A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA)

International Journal of Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles